Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
Why now
Thesis: Takeover clears a hurdle, supporting biotech deal momentum
Catalyst to watch: Regulatory clearance and closing timeline
Main risk: Pay rejection hints at integration or governance issues
Why it matters
Shareholder approval of the Merck KGaA takeover advances deal closure while rejecting pay signals governance friction.
Sources
- googlenews · news.google.com · 2026-09-26 03:57 UTC